Moderna on Monday announced it has applied for emergency use authorization from the Food and Drug Administration for its COVID-19 vaccine candidate. The company said an analysis of 196 cases showed that its vaccine is 94.1 percent effective after earlier this month revealing preliminary phase-three trial data. Additionally, data showed that the vaccine was 100 percent effective at preventing severe COVID-19 cases, Moderna said. This is the second company to seek FDA emergency authorization for a COVID-19 vaccine after Pfizer, which applied after data showed its vaccine to be about 95 percent effective. Moderna CEO Stéphane Bancel told The New York Times that should the vaccine receive emergency FDA approval, the first doses could potentially be given by Dec. 21.

Scroll for 5 things you
need to know now